{"ticker": {"uuid": "20d0df0e-55a3-44aa-ac45-8775fccac5e4", "symbol": "MRKR", "name": "Marker Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wainwright reiterates Buy on Marker Therapeutics stock, $10 target By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Marker Therapeutics (NASDAQ:MRKR) after a fireside chat with the company's management. The conversation focused on their lead cell therapy program, MT-601, developed for lymphoma and pancreatic cancer, whic", "url": "https://ca.investing.com/news/stock-market-news/wainwright-reiterates-buy-on-marker-therapeutics-stock-10-target-93CH-4729076", "source_name": "Investing.com Canada", "published_at": "2026-07-10T12:09:55", "published_display": "10 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $8", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQak9FX3BxN3dwWHJBMnhFZTlVdmNTWlhVTGQwbm1rQkF3T3NBVjBpSnNHdkxyclJTbFdOSmxBWktyTDBEWXZuNkdYRU5jODFreGEzcVlnWmhDYXktS1l2cFZhaFBqRUI3NHUtUHBTQzBpWG16cVRfUjZxSE53YnZnU0ptenBqSUJGV1F4eHNIdjNpOXdFYlRrS0VmR2dtVldiOG5sdmZYRGtpVXRiZVZONTZJdm92RGs?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-10T08:11:43+00:00", "published_display": "10 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Profit Outlook", "summary": "Marker Therapeutics (NASDAQ:MRKR) is projected by analysts to achieve profitability around 2028, after incurring a final loss in 2027. This breakeven projection relies on a highly buoyant average annual growth rate of 69%. The company currently has no debt, which reduces investme", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrkr/marker-therapeutics/news/marker-therapeutics-incs-nasdaqmrkr-profit-outlook", "source_name": "Simply Wall Street", "published_at": "2026-07-02T10:39:37", "published_display": "02 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Marker Therapeutics, Inc. \u2013 NASDAQ:MRKR", "summary": "This article provides a financial metric for Marker Therapeutics, Inc. (NASDAQ: MRKR), specifically its \"Price to book forward.\" The content is primarily a placeholder or incomplete financial data from TradingView, indicating that the market for MRKR was closed with no trades at ", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T17:10:28", "published_display": "29 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Marker Therapeutics, Inc. \u2013 NASDAQ:MRKR", "summary": "This article provides financial information for Marker Therapeutics, Inc. (NASDAQ:MRKR), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication, with no trades reported. The content appears to be a financia", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:40:37", "published_display": "26 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/zacks-industry-outlook-indivior-aurinia-085900669.html", "source_name": "Zacks", "published_at": "2026-06-26T08:59:00+00:00", "published_display": "26 Jun 2026 08:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics, Inc. Actuals & Estimates (NASDAQ:MRKR)", "summary": "This article provides an overview of Marker Therapeutics, Inc. (NASDAQ: MRKR) financials, stock performance, and analyst forecasts. It covers key metrics such as current stock price, historical highs and lows, market capitalization, earnings, revenue, and EBITDA. The company's ne", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:37", "published_display": "26 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Marker Therapeutics, Inc. \u2013 NASDAQ:MRKR", "summary": "This article provides financial data for Marker Therapeutics, Inc. (NASDAQ: MRKR), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or an incomplete financial data page from TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:40:25", "published_display": "26 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRKR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Marker Therapeutics, Inc. (MRKR) stock, including analyst price targets and predictions for 2027. It details recent stock performance, financial metrics like revenue and earnings per share, and other company information such as market capitali", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T06:11:01", "published_display": "25 Jun 2026 06:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Marker Therapeutics, Inc. \u2013 NASDAQ:MRKR", "summary": "This article provides the enterprise value to EBIT forward for Marker Therapeutics, Inc. (NASDAQ: MRKR). It is presented as part of financial data available on TradingView, which offers various market tools and information for investors. The content primarily focuses on presentin", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T18:10:32", "published_display": "24 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics (MRKR) Slides 1.48% as Stock Hovers Near Key Support Level - Value Area Low", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOTEx2dVpOZTRfQlZ6V2JNd0RyRmY2TDhkWDA5cmZkYzljaWRjZ1JSa0lLZUFkam5vOXRGcmU5ZTZudlV6eVd0eE9FVXBuQXJhc0ZMWkVXa1BpT2VxVG8yMnFyejBEdG96SDZTOWE4bE5LVHU3cWU5TG5nb2tGd1dIdzVDZmo2VWFIOFJ2NUhSTlV3V0U5SGNOZlpqUDZwWjV3MV8yU3d5TnJiNTVCVXdLa193UFVtdHlZMkE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Marker Therapeutics Inc (MRKR), highlighting its current price momentum score of 5.39 within the Biotechnology & Medical Research industry. It identifies the stock trading between a resistance level of $1.50 and a support level of $1.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/technical", "source_name": "TradingKey", "published_at": "2026-06-18T22:40:23", "published_display": "18 Jun 2026 22:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Valuation: PE, PB & Fair Value Analysis", "summary": "Marker Therapeutics Inc (MRKR) currently has a valuation score of 8.40, placing it 137th out of 389 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -2.38, showing a significant percentage difference from both its recent high and low P", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T21:41:11", "published_display": "18 Jun 2026 21:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Institutional Confidence", "summary": "Marker Therapeutics Inc (MRKR) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 26.04%, marking a 17.09% increase quarter-over-quarter. James Simons i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:13", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Marker Therapeutics Inc (MRKR) currently has an earnings forecast score of 8.00, ranking 163rd in its industry. Analysts have set an average price target of $9.00 for MRKR, with a \"Buy\" rating from most analysts. The company's expected revenue for the next quarter is $682.00K, an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:53", "published_display": "18 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on the revenue breakdown of Marker Therapeutics Inc (MRKR). It states that relevant data regarding the company's revenue by business segments and by region has not yet been disclosed. The article provides a stock quote for MRKR, showing a slig", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:54", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of the dividend and stock split history for Marker Therapeutics Inc (MRKR). It notes that the company has not distributed any dividends over the past five years. The page also details several 10-to-1 merger-related stock splits that occurred on J", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:54", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics (MRKR) Holds Steady Above Support as Biotech Sector Shows Mixed Signals - OBV Divergence", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQTzRpWUdmNXZ6elVRYWViY0ZwSmFLeEItaHY2cFpRb2s1MmtGd1NzUWkzbllwMm5OV29NMDdUa21McTJlZXFFbmdTc3dZVnJVQTRYTXBUNUltTjNaR0R0WEZ0YjNLN0hNMlNKSXZtSzZRNFZPOWxJUXRJbkx1bG15WnYwQThTT0JaM1FPYXd4VHVKUE9lZWJIb1NSQVVJM3ZwcENBOUoyUXUxbERydW9kMVc2Q2RDeU1DdV9QOHdDNjh3TG1QaFg3OGpDR2ZMMVFiX2c?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics (MRKR) Holds Steady Above Support as Biotech Sector Shows Mixed Signals - Day Trade Opportunities", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNR3hsNG1ySjhITFl3TDNWZDJBVDZqd1M5QlJGU1RPVUZoRk91UldINU5KNEYtbFFQbUprVUVRODQ0VmZJTUJjcWt2blhTWnJZNENTb2RrRjRGRmJ2aE9qdmtaM2g0WUVkV05Jd3NhRHdjX1dxVE5CYlppdlRnemtVdGNJM0tBNGJnc2RRTjFfdFhYTUtWZTRqb0xJOFp2X3VKVWoyNEFydHF2TnBaVWZfdUpxdVY1RDJIZHVXcTc5R2RndXpkUlhrUFRrSFpPb0V1WGowMg?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRKR - Marker Therapeutics Inc Stock Price and Quote", "summary": "This article provides a comprehensive overview of Marker Therapeutics Inc (MRKR) stock, including its latest price, financial data, performance metrics, and recent news. It details key financial figures, stock performance comparisons, analyst ratings, and a chronology of signific", "url": "https://finviz.com/stock?t=MRKR", "source_name": "Finviz", "published_at": "2026-05-30T02:39:25", "published_display": "30 May 2026 02:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Marker Therapeutics (NASDAQ: MRKR) after the company reported its first-quarter 2026 financial results. The company holds more cash than debt, and its liquid assets exceed short-term obligations, indicating", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-marker-therapeutics-stock-rating-at-buy-93CH-4650874", "source_name": "Investing.com Canada", "published_at": "2026-05-24T13:38:57", "published_display": "24 May 2026 13:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Merck & Company (MRK) and Cullinan Management (CGEM)", "summary": "This article provides analyst insights on three healthcare companies: Marker Therapeutics (MRKR), Merck & Company (MRK), and Cullinan Management (CGEM). Analysts reiterated \"Buy\" ratings for Marker Therapeutics and Cullinan Management, with significant upside potential, while Mer", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/2036715/analysts-offer-insights-on-healthcare-companies-marker-therapeutics-mrkr-merck-company-mrk-and-cullinan-management-cgem/", "source_name": "The Globe and Mail", "published_at": "2026-05-22T16:09:58", "published_display": "22 May 2026 16:09", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Marker Therapeutics stock rating at buy", "summary": "H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Marker Therapeutics (NASDAQ:MRKR) following its first-quarter 2026 financial results. The company reported $1.4 million in operating cash use, ending the quarter with $15.6 million in cash, cash equivalents", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-marker-therapeutics-stock-rating-at-buy-93CH-4701095", "source_name": "Investing.com", "published_at": "2026-05-20T12:09:40", "published_display": "20 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $10", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQNU9Qak1aRWYtWlJMS0N2THphTmZIRFMtOXktREZRTlA2WGN3SWN2RWNoU0Eyb3kyVE15d2NXMHhYY2M4WlE4Rk4xSml2d0JKa3Y4WDRDM0R2elJTZXZFTXNuTmtPZE1tZTU5WkpXVTVodk1IY0xJODkzTGhWZmFLREMtdWZMdjJCNnRtOXNLVV85c0JHcFJfRlJweHFRb3dSNE90bHg2Unc5Ym5xTk01VTdaalU4bndQY2c?oc=5", "source_name": "Moomoo", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRKR: Net loss improved to $3.2M in Q1 2026, with cash funding expected through Q1 2027", "summary": "Marker Therapeutics (MRKR) reported an improved net loss of $3.2 million in Q1 2026, attributed to lower expenses and increased grant income. The company anticipates its $15.6 million cash reserves will fund operations until Q1 2027. However, the report highlights substantial dou", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3337620:0-mrkr-net-loss-improved-to-3-2m-in-q1-2026-with-cash-funding-expected-through-q1-2027/", "source_name": "TradingView", "published_at": "2026-05-16T09:43:20", "published_display": "16 May 2026 09:43", "sentiment": "positive", "sentiment_pct": 59, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics, Inc. Q1 2026: Net loss $(3.18M), Diluted EPS $(0.16) \u2014 10-Q Summary", "summary": "Marker Therapeutics, Inc. reported a net loss of $(3.18M) in Q1 2026, an improvement from a $(4.45M) loss in Q1 2025, with diluted EPS at $(0.16). This improvement was partly due to increased grant income and progress in clinical trials, particularly with their APOLLO study and a", "url": "https://www.tradingview.com/news/tradingview:6eeaed0a40320:0-marker-therapeutics-inc-q1-2026-net-loss-3-18m-diluted-eps-0-16-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-15T21:10:35", "published_display": "15 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics (MRKR) narrows Q1 2026 loss but warns on going concern", "summary": "Marker Therapeutics (MRKR) reported a narrowed net loss of $3.2 million in Q1 2026, down from $4.4 million a year ago, attributing the improvement to reduced operating expenses and increased grant income. However, the pre-revenue biotech firm currently has $15.6 million in cash, ", "url": "https://www.stocktitan.net/sec-filings/MRKR/10-q-marker-therapeutics-inc-quarterly-earnings-report-2baa51242594.html", "source_name": "Stock Titan", "published_at": "2026-05-15T21:10:35", "published_display": "15 May 2026 21:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TradingKey", "summary": "This page provides an overview of Marker Therapeutics Inc. (MRKR) on the TradingKey platform. It displays basic financial information like market capitalization, current stock price, and price change. The page also offers sections for financials, discussions, and analysis, along ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/comments", "source_name": "TradingKey", "published_at": "2026-05-12T07:40:26", "published_display": "12 May 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Number of shareholders of Marker Therapeutics, Inc. \u2013 NASDAQ:MRKR", "summary": "This article provides details regarding the number of shareholders for Marker Therapeutics, Inc. (NASDAQ: MRKR). It appears to be a stub or a data point from a financial platform, indicating the company's stock market presence on Nasdaq. The content does not include the actual nu", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-11T02:09:55", "published_display": "11 May 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics, Inc. (MRKR) reports Q4 loss, tops revenue estimates", "summary": "Marker Therapeutics, Inc. (MRKR) announced a fourth-quarter loss per share that was narrower than the Zacks Consensus Estimate, while its revenue exceeded expectations. The biotechnology company reported progress in clinical trials for its multi-tumor antigen-specific T cell (MTA", "url": "http://www.msn.com/en-us/money/other/marker-therapeutics-inc-mrkr-reports-q4-loss-tops-revenue-estimates/ar-AA1YWEK1?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-08T05:09:55", "published_display": "08 May 2026 05:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics (NASDAQ: MRKR) holders back share increase but reject voting change", "summary": "Marker Therapeutics (NASDAQ: MRKR) stockholders approved a Charter Amendment to significantly increase the authorized common shares from 30 million to 130 million, providing the company with more flexibility for future equity issuances. While this key proposal passed, along with ", "url": "https://www.stocktitan.net/sec-filings/MRKR/8-k-marker-therapeutics-inc-reports-material-event-e62b0f3dab75.html", "source_name": "Stock Titan", "published_at": "2026-05-04T20:39:43", "published_display": "04 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Shareholders Approve Governance and Capital Changes", "summary": "Marker Therapeutics shareholders recently re-elected all director nominees, approved executive compensation, and ratified their independent auditor. They also significantly increased the company's authorized common stock from 30 million to 130 million shares, providing flexibilit", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MRKR/pressreleases/1726344/marker-therapeutics-shareholders-approve-governance-and-capital-changes/", "source_name": "The Globe and Mail", "published_at": "2026-05-02T14:39:59", "published_display": "02 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Total debt per share of Marker Therapeutics, Inc. \u2013 FWB:GX1", "summary": "This article displays information regarding the total debt per share of Marker Therapeutics, Inc. (FWB:GX1). The content focuses on financial data for the company's stock on the Frankfurt Stock Exchange. No specific debt figures are presented, but the structure suggests this is a", "url": "https://www.tradingview.com/symbols/FWB-GX1/financials-statistics-and-ratios/total-debt-per-share/", "source_name": "TradingView", "published_at": "2026-04-05T12:40:09", "published_display": "05 Apr 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EBITDA per share of Marker Therapeutics, Inc. \u2013 FWB:GX1", "summary": "This article provides access to the EBITDA per share financial data for Marker Therapeutics, Inc. (FWB:GX1) on TradingView. It highlights that the market for GX1 on the Frankfurt Stock Exchange is currently closed with no trades. The content primarily serves as a gateway to finan", "url": "https://www.tradingview.com/symbols/FWB-GX1/financials-statistics-and-ratios/ebitda-per-share/", "source_name": "TradingView", "published_at": "2026-04-05T07:39:31", "published_display": "05 Apr 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQYVBxRklTQTQ1eG9YM1ZsdTlucFRNODZLTGhUbzZCOXJhamozUFFSeHhhN0NQLV9fTFoxbHh1bHpjT1FpQjZFc1NCaDB4dVVsQTNpOVEwWTNudFR5clZvdmo3X2dCdWJTZDV1RDluNzIwUTRaTzRETGRWVGNIN0lQb3RENGRXX1VfR05tYjZxeVRYSGg4WjJ5UXdtTUxEUG1TWm9PT3NIbjlhQjVLYTdwM2xrVDNUbERuazVtRVBGeTVLRnE2bnFzMGhmQzJzbldiX3haNGR3bVdHWWNfS3c?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics\u2019 MAR-T Cell Technology", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOTUFGcHBrVmpIRHhWcGp3R0UwUXFLZldGWU95REZ6QU5XMkdob0I2amwxSUp0TnRSaFJaa1psSUFOMGZYeDFGMDFvSUdEekhTa01aWTBXVEZ6QnoxelRWZHdlSUk3RnZUaktFT2ZsN0F3Q05ZRWQtNkpoa1JsWGRwQTVwd3VrNG1TeXc?oc=5", "source_name": "Market source", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Would You Still Hold Marker Therapeutics Stock If It Fell Another 30%?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPaUxKYWNGYjFFSXBkSXFNMFB6WHN6Z0lSNEl5TjU2dHVHeEJILU5tcTE4Um9vV1hvZDIybXYtOUZPU1RHQ1FpeHZtZTQ4ZTBXOXNidkJnNXhlRlc2WXB0SGpaUTRiN2U3MDVuVkg3YWM5akZicDVtMVprbkhQMm9QaHZ0VXJ2dFltQU9zMWVFekpJaDZnUGM1a1dWcGF0dGdHTksySmJpTEU2R3lDd3pzREZDQ3hkQ2hyc2Q3MG5ocVhfQVpFY0RXWTVaUUstdV80MVpPRUJR?oc=5", "source_name": "Trefis", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxONGwtY0g4NW1qNVRtUjNZRmxETjJDUE11TTZpQkZfU1ZRWXl2X2lnSExrVFFsaVEzRUh1Z0k1SVoyeUhwd3h3N1NRQXZhdVVLdEdDMm44V3g1TGl6ZmZyX1QtamYzc1dTYjhOWnhqLW81YkJHbmtxNnB5RkIxQmFEcEM4N3lsZ1lpa2c?oc=5", "source_name": "Market source", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeut (MRKR) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBmX0l3M3JWeF95dUJVcm4xYnNrT1A4dFN2NzF2QXNDb1FGdGR3Z3FLNXFXeDNLTlAwb3FCcVR6MHhmcHdSaG1CdXhkVVJzZw?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-13T20:09:14+00:00", "published_display": "13 Sep 2020 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Wainwright reiterates Buy on Marker Therapeutics stock, $10 target By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Marker Therapeutics (NASDAQ:MRKR) after a fireside chat with the company's management. The conversation focused on their lead cell therapy program, MT-601, developed for lymphoma and pancreatic cancer, whic", "url": "https://ca.investing.com/news/stock-market-news/wainwright-reiterates-buy-on-marker-therapeutics-stock-10-target-93CH-4729076", "source_name": "Investing.com Canada", "published_at": "2026-07-10T12:09:55", "published_display": "10 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $8", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQak9FX3BxN3dwWHJBMnhFZTlVdmNTWlhVTGQwbm1rQkF3T3NBVjBpSnNHdkxyclJTbFdOSmxBWktyTDBEWXZuNkdYRU5jODFreGEzcVlnWmhDYXktS1l2cFZhaFBqRUI3NHUtUHBTQzBpWG16cVRfUjZxSE53YnZnU0ptenBqSUJGV1F4eHNIdjNpOXdFYlRrS0VmR2dtVldiOG5sdmZYRGtpVXRiZVZONTZJdm92RGs?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-10T08:11:43+00:00", "published_display": "10 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Profit Outlook", "summary": "Marker Therapeutics (NASDAQ:MRKR) is projected by analysts to achieve profitability around 2028, after incurring a final loss in 2027. This breakeven projection relies on a highly buoyant average annual growth rate of 69%. The company currently has no debt, which reduces investme", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrkr/marker-therapeutics/news/marker-therapeutics-incs-nasdaqmrkr-profit-outlook", "source_name": "Simply Wall Street", "published_at": "2026-07-02T10:39:37", "published_display": "02 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Marker Therapeutics, Inc. \u2013 NASDAQ:MRKR", "summary": "This article provides a financial metric for Marker Therapeutics, Inc. (NASDAQ: MRKR), specifically its \"Price to book forward.\" The content is primarily a placeholder or incomplete financial data from TradingView, indicating that the market for MRKR was closed with no trades at ", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T17:10:28", "published_display": "29 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Marker Therapeutics, Inc. \u2013 NASDAQ:MRKR", "summary": "This article provides financial information for Marker Therapeutics, Inc. (NASDAQ:MRKR), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication, with no trades reported. The content appears to be a financia", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:40:37", "published_display": "26 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/zacks-industry-outlook-indivior-aurinia-085900669.html", "source_name": "Zacks", "published_at": "2026-06-26T08:59:00+00:00", "published_display": "26 Jun 2026 08:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics, Inc. Actuals & Estimates (NASDAQ:MRKR)", "summary": "This article provides an overview of Marker Therapeutics, Inc. (NASDAQ: MRKR) financials, stock performance, and analyst forecasts. It covers key metrics such as current stock price, historical highs and lows, market capitalization, earnings, revenue, and EBITDA. The company's ne", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:37", "published_display": "26 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Marker Therapeutics, Inc. \u2013 NASDAQ:MRKR", "summary": "This article provides financial data for Marker Therapeutics, Inc. (NASDAQ: MRKR), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or an incomplete financial data page from TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:40:25", "published_display": "26 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRKR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Marker Therapeutics, Inc. (MRKR) stock, including analyst price targets and predictions for 2027. It details recent stock performance, financial metrics like revenue and earnings per share, and other company information such as market capitali", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T06:11:01", "published_display": "25 Jun 2026 06:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Marker Therapeutics, Inc. \u2013 NASDAQ:MRKR", "summary": "This article provides the enterprise value to EBIT forward for Marker Therapeutics, Inc. (NASDAQ: MRKR). It is presented as part of financial data available on TradingView, which offers various market tools and information for investors. The content primarily focuses on presentin", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T18:10:32", "published_display": "24 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics (MRKR) Slides 1.48% as Stock Hovers Near Key Support Level - Value Area Low", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOTEx2dVpOZTRfQlZ6V2JNd0RyRmY2TDhkWDA5cmZkYzljaWRjZ1JSa0lLZUFkam5vOXRGcmU5ZTZudlV6eVd0eE9FVXBuQXJhc0ZMWkVXa1BpT2VxVG8yMnFyejBEdG96SDZTOWE4bE5LVHU3cWU5TG5nb2tGd1dIdzVDZmo2VWFIOFJ2NUhSTlV3V0U5SGNOZlpqUDZwWjV3MV8yU3d5TnJiNTVCVXdLa193UFVtdHlZMkE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Marker Therapeutics Inc (MRKR), highlighting its current price momentum score of 5.39 within the Biotechnology & Medical Research industry. It identifies the stock trading between a resistance level of $1.50 and a support level of $1.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/technical", "source_name": "TradingKey", "published_at": "2026-06-18T22:40:23", "published_display": "18 Jun 2026 22:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Valuation: PE, PB & Fair Value Analysis", "summary": "Marker Therapeutics Inc (MRKR) currently has a valuation score of 8.40, placing it 137th out of 389 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -2.38, showing a significant percentage difference from both its recent high and low P", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T21:41:11", "published_display": "18 Jun 2026 21:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Institutional Confidence", "summary": "Marker Therapeutics Inc (MRKR) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 26.04%, marking a 17.09% increase quarter-over-quarter. James Simons i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:13", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Marker Therapeutics Inc (MRKR) currently has an earnings forecast score of 8.00, ranking 163rd in its industry. Analysts have set an average price target of $9.00 for MRKR, with a \"Buy\" rating from most analysts. The company's expected revenue for the next quarter is $682.00K, an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:53", "published_display": "18 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on the revenue breakdown of Marker Therapeutics Inc (MRKR). It states that relevant data regarding the company's revenue by business segments and by region has not yet been disclosed. The article provides a stock quote for MRKR, showing a slig", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:54", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Inc (MRKR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of the dividend and stock split history for Marker Therapeutics Inc (MRKR). It notes that the company has not distributed any dividends over the past five years. The page also details several 10-to-1 merger-related stock splits that occurred on J", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:54", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics (MRKR) Holds Steady Above Support as Biotech Sector Shows Mixed Signals - OBV Divergence", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQTzRpWUdmNXZ6elVRYWViY0ZwSmFLeEItaHY2cFpRb2s1MmtGd1NzUWkzbllwMm5OV29NMDdUa21McTJlZXFFbmdTc3dZVnJVQTRYTXBUNUltTjNaR0R0WEZ0YjNLN0hNMlNKSXZtSzZRNFZPOWxJUXRJbkx1bG15WnYwQThTT0JaM1FPYXd4VHVKUE9lZWJIb1NSQVVJM3ZwcENBOUoyUXUxbERydW9kMVc2Q2RDeU1DdV9QOHdDNjh3TG1QaFg3OGpDR2ZMMVFiX2c?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics (MRKR) Holds Steady Above Support as Biotech Sector Shows Mixed Signals - Day Trade Opportunities", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNR3hsNG1ySjhITFl3TDNWZDJBVDZqd1M5QlJGU1RPVUZoRk91UldINU5KNEYtbFFQbUprVUVRODQ0VmZJTUJjcWt2blhTWnJZNENTb2RrRjRGRmJ2aE9qdmtaM2g0WUVkV05Jd3NhRHdjX1dxVE5CYlppdlRnemtVdGNJM0tBNGJnc2RRTjFfdFhYTUtWZTRqb0xJOFp2X3VKVWoyNEFydHF2TnBaVWZfdUpxdVY1RDJIZHVXcTc5R2RndXpkUlhrUFRrSFpPb0V1WGowMg?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRKR - Marker Therapeutics Inc Stock Price and Quote", "summary": "This article provides a comprehensive overview of Marker Therapeutics Inc (MRKR) stock, including its latest price, financial data, performance metrics, and recent news. It details key financial figures, stock performance comparisons, analyst ratings, and a chronology of signific", "url": "https://finviz.com/stock?t=MRKR", "source_name": "Finviz", "published_at": "2026-05-30T02:39:25", "published_display": "30 May 2026 02:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Marker Therapeutics (NASDAQ: MRKR) after the company reported its first-quarter 2026 financial results. The company holds more cash than debt, and its liquid assets exceed short-term obligations, indicating", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-marker-therapeutics-stock-rating-at-buy-93CH-4650874", "source_name": "Investing.com Canada", "published_at": "2026-05-24T13:38:57", "published_display": "24 May 2026 13:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Merck & Company (MRK) and Cullinan Management (CGEM)", "summary": "This article provides analyst insights on three healthcare companies: Marker Therapeutics (MRKR), Merck & Company (MRK), and Cullinan Management (CGEM). Analysts reiterated \"Buy\" ratings for Marker Therapeutics and Cullinan Management, with significant upside potential, while Mer", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/2036715/analysts-offer-insights-on-healthcare-companies-marker-therapeutics-mrkr-merck-company-mrk-and-cullinan-management-cgem/", "source_name": "The Globe and Mail", "published_at": "2026-05-22T16:09:58", "published_display": "22 May 2026 16:09", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Marker Therapeutics stock rating at buy", "summary": "H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Marker Therapeutics (NASDAQ:MRKR) following its first-quarter 2026 financial results. The company reported $1.4 million in operating cash use, ending the quarter with $15.6 million in cash, cash equivalents", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-marker-therapeutics-stock-rating-at-buy-93CH-4701095", "source_name": "Investing.com", "published_at": "2026-05-20T12:09:40", "published_display": "20 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $10", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQNU9Qak1aRWYtWlJMS0N2THphTmZIRFMtOXktREZRTlA2WGN3SWN2RWNoU0Eyb3kyVE15d2NXMHhYY2M4WlE4Rk4xSml2d0JKa3Y4WDRDM0R2elJTZXZFTXNuTmtPZE1tZTU5WkpXVTVodk1IY0xJODkzTGhWZmFLREMtdWZMdjJCNnRtOXNLVV85c0JHcFJfRlJweHFRb3dSNE90bHg2Unc5Ym5xTk01VTdaalU4bndQY2c?oc=5", "source_name": "Moomoo", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRKR: Net loss improved to $3.2M in Q1 2026, with cash funding expected through Q1 2027", "summary": "Marker Therapeutics (MRKR) reported an improved net loss of $3.2 million in Q1 2026, attributed to lower expenses and increased grant income. The company anticipates its $15.6 million cash reserves will fund operations until Q1 2027. However, the report highlights substantial dou", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3337620:0-mrkr-net-loss-improved-to-3-2m-in-q1-2026-with-cash-funding-expected-through-q1-2027/", "source_name": "TradingView", "published_at": "2026-05-16T09:43:20", "published_display": "16 May 2026 09:43", "sentiment": "positive", "sentiment_pct": 59, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics, Inc. Q1 2026: Net loss $(3.18M), Diluted EPS $(0.16) \u2014 10-Q Summary", "summary": "Marker Therapeutics, Inc. reported a net loss of $(3.18M) in Q1 2026, an improvement from a $(4.45M) loss in Q1 2025, with diluted EPS at $(0.16). This improvement was partly due to increased grant income and progress in clinical trials, particularly with their APOLLO study and a", "url": "https://www.tradingview.com/news/tradingview:6eeaed0a40320:0-marker-therapeutics-inc-q1-2026-net-loss-3-18m-diluted-eps-0-16-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-15T21:10:35", "published_display": "15 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics (MRKR) narrows Q1 2026 loss but warns on going concern", "summary": "Marker Therapeutics (MRKR) reported a narrowed net loss of $3.2 million in Q1 2026, down from $4.4 million a year ago, attributing the improvement to reduced operating expenses and increased grant income. However, the pre-revenue biotech firm currently has $15.6 million in cash, ", "url": "https://www.stocktitan.net/sec-filings/MRKR/10-q-marker-therapeutics-inc-quarterly-earnings-report-2baa51242594.html", "source_name": "Stock Titan", "published_at": "2026-05-15T21:10:35", "published_display": "15 May 2026 21:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "This page provides an overview of Marker Therapeutics Inc. (MRKR) on the TradingKey platform. It displays basic financial information like market capitalization, current stock price, and price change. The page also offers sections for financials, discussions, and analysis, along ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mrkr/comments", "source_name": "TradingKey", "published_at": "2026-05-12T07:40:26", "published_display": "12 May 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Marker Therapeutics, Inc. \u2013 NASDAQ:MRKR", "summary": "This article provides details regarding the number of shareholders for Marker Therapeutics, Inc. (NASDAQ: MRKR). It appears to be a stub or a data point from a financial platform, indicating the company's stock market presence on Nasdaq. The content does not include the actual nu", "url": "https://www.tradingview.com/symbols/NASDAQ-MRKR/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-11T02:09:55", "published_display": "11 May 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics, Inc. (MRKR) reports Q4 loss, tops revenue estimates", "summary": "Marker Therapeutics, Inc. (MRKR) announced a fourth-quarter loss per share that was narrower than the Zacks Consensus Estimate, while its revenue exceeded expectations. The biotechnology company reported progress in clinical trials for its multi-tumor antigen-specific T cell (MTA", "url": "http://www.msn.com/en-us/money/other/marker-therapeutics-inc-mrkr-reports-q4-loss-tops-revenue-estimates/ar-AA1YWEK1?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-08T05:09:55", "published_display": "08 May 2026 05:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics (NASDAQ: MRKR) holders back share increase but reject voting change", "summary": "Marker Therapeutics (NASDAQ: MRKR) stockholders approved a Charter Amendment to significantly increase the authorized common shares from 30 million to 130 million, providing the company with more flexibility for future equity issuances. While this key proposal passed, along with ", "url": "https://www.stocktitan.net/sec-filings/MRKR/8-k-marker-therapeutics-inc-reports-material-event-e62b0f3dab75.html", "source_name": "Stock Titan", "published_at": "2026-05-04T20:39:43", "published_display": "04 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Shareholders Approve Governance and Capital Changes", "summary": "Marker Therapeutics shareholders recently re-elected all director nominees, approved executive compensation, and ratified their independent auditor. They also significantly increased the company's authorized common stock from 30 million to 130 million shares, providing flexibilit", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MRKR/pressreleases/1726344/marker-therapeutics-shareholders-approve-governance-and-capital-changes/", "source_name": "The Globe and Mail", "published_at": "2026-05-02T14:39:59", "published_display": "02 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total debt per share of Marker Therapeutics, Inc. \u2013 FWB:GX1", "summary": "This article displays information regarding the total debt per share of Marker Therapeutics, Inc. (FWB:GX1). The content focuses on financial data for the company's stock on the Frankfurt Stock Exchange. No specific debt figures are presented, but the structure suggests this is a", "url": "https://www.tradingview.com/symbols/FWB-GX1/financials-statistics-and-ratios/total-debt-per-share/", "source_name": "TradingView", "published_at": "2026-04-05T12:40:09", "published_display": "05 Apr 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EBITDA per share of Marker Therapeutics, Inc. \u2013 FWB:GX1", "summary": "This article provides access to the EBITDA per share financial data for Marker Therapeutics, Inc. (FWB:GX1) on TradingView. It highlights that the market for GX1 on the Frankfurt Stock Exchange is currently closed with no trades. The content primarily serves as a gateway to finan", "url": "https://www.tradingview.com/symbols/FWB-GX1/financials-statistics-and-ratios/ebitda-per-share/", "source_name": "TradingView", "published_at": "2026-04-05T07:39:31", "published_display": "05 Apr 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQYVBxRklTQTQ1eG9YM1ZsdTlucFRNODZLTGhUbzZCOXJhamozUFFSeHhhN0NQLV9fTFoxbHh1bHpjT1FpQjZFc1NCaDB4dVVsQTNpOVEwWTNudFR5clZvdmo3X2dCdWJTZDV1RDluNzIwUTRaTzRETGRWVGNIN0lQb3RENGRXX1VfR05tYjZxeVRYSGg4WjJ5UXdtTUxEUG1TWm9PT3NIbjlhQjVLYTdwM2xrVDNUbERuazVtRVBGeTVLRnE2bnFzMGhmQzJzbldiX3haNGR3bVdHWWNfS3c?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics\u2019 MAR-T Cell Technology", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOTUFGcHBrVmpIRHhWcGp3R0UwUXFLZldGWU95REZ6QU5XMkdob0I2amwxSUp0TnRSaFJaa1psSUFOMGZYeDFGMDFvSUdEekhTa01aWTBXVEZ6QnoxelRWZHdlSUk3RnZUaktFT2ZsN0F3Q05ZRWQtNkpoa1JsWGRwQTVwd3VrNG1TeXc?oc=5", "source_name": "Market source", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Would You Still Hold Marker Therapeutics Stock If It Fell Another 30%?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPaUxKYWNGYjFFSXBkSXFNMFB6WHN6Z0lSNEl5TjU2dHVHeEJILU5tcTE4Um9vV1hvZDIybXYtOUZPU1RHQ1FpeHZtZTQ4ZTBXOXNidkJnNXhlRlc2WXB0SGpaUTRiN2U3MDVuVkg3YWM5akZicDVtMVprbkhQMm9QaHZ0VXJ2dFltQU9zMWVFekpJaDZnUGM1a1dWcGF0dGdHTksySmJpTEU2R3lDd3pzREZDQ3hkQ2hyc2Q3MG5ocVhfQVpFY0RXWTVaUUstdV80MVpPRUJR?oc=5", "source_name": "Trefis", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxONGwtY0g4NW1qNVRtUjNZRmxETjJDUE11TTZpQkZfU1ZRWXl2X2lnSExrVFFsaVEzRUh1Z0k1SVoyeUhwd3h3N1NRQXZhdVVLdEdDMm44V3g1TGl6ZmZyX1QtamYzc1dTYjhOWnhqLW81YkJHbmtxNnB5RkIxQmFEcEM4N3lsZ1lpa2c?oc=5", "source_name": "Market source", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marker Therapeut (MRKR) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBmX0l3M3JWeF95dUJVcm4xYnNrT1A4dFN2NzF2QXNDb1FGdGR3Z3FLNXFXeDNLTlAwb3FCcVR6MHhmcHdSaG1CdXhkVVJzZw?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-13T20:09:14+00:00", "published_display": "13 Sep 2020 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 48, "sentiment_summary": {"positive": 14, "negative": 5, "neutral": 29, "score": 54, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 73, "events": [{"event": "general", "label": "Market update", "weight": 9.35, "count": 17}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 1.51, "latest_week": "2026-07-10", "one_week_move": 2.7, "four_week_move": 9.4, "twelve_week_move": -9.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.44511, "market_dynamics_buy_signal": false, "relative_strength": -3.52685, "fair_value_gap": -45.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.5668, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.7% over one week, +9.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com Canada", "count": 2}, {"label": "Donan\u0131mHaber", "count": 2}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 17}, {"label": "Market update", "count": 17}, {"label": "Analyst action", "count": 6}, {"label": "Balance sheet", "count": 5}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.7% over one week, +9.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Wainwright reiterates Buy on Marker Therapeutics stock, $10 target By Investing.com"}], "updated_at": "2026-07-16T10:34:54.549607+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}